Da Volterra Announces Positive Results of a Phase 1 Drug-Drug Interaction Study
Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota, announced the results of DAV132- CL-1005, a Phase 1 clinical study which investigated the potential effect of DAV132 on the bioavailability […]